NCT06840054View on ClinicalTrials.gov

The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

Sodium Pentaborate Pentahydrate

will receive 1000 mg of sodium pentaborate pentahydrate daily along with donepezil.

DRUG

Placebo

will receive a placebo along with donepezil

All Listed Sponsors
lead

Tabriz University of Medical Sciences

OTHER